DDInter1042 DDInter1826
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolazamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Tolazamide {u} (Compound) binds {v} (Gene) KCNJ1
Tolazamide {u} (Compound) upregulates {v} (Gene) TSC22D3
Tolazamide {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Tolazamide {u} (Compound) downregulates {v} (Gene) GDF15
Tolazamide {u} (Compound) causes {v} (Side Effect) Headache
Tolazamide (Compound) resembles Tolbutamide (Compound)
Tolazamide (Compound) treats type 2 diabetes mellitus (Disease)
Tolazamide (Compound) binds KCNJ1 (Gene)
Tolazamide (Compound) upregulates TSC22D3 (Gene)
Tolazamide (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class)
Tolazamide (Compound) downregulates GDF15 (Gene)
Tolazamide (Compound) causes Headache (Side Effect)